Mineralys Therapeutics

Mineralys Therapeutics Advances in Its Pivotal Hypertension Trial with First Dose of Lorundrostat Administered

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has reached a critical milestone in its quest to revolutionize hypertension treatment. The company recently announced that the first subject in the …

Mineralys Therapeutics Advances in Its Pivotal Hypertension Trial with First Dose of Lorundrostat Administered Read More